October 26, 2026
Bristol-Myers Squibb, Natco Pharma, AbbVie and other pharmaceutical companies have sought permission to file an interlocutory appeal for a sprawling antitrust multidistrict litigation over Celgene Corp.'s cancer drug Revlimid to the Third Circuit after a New Jersey federal judge refused to toss it.
September 30, 2026
A New Jersey federal judge Tuesday refused to throw out sprawling antitrust multidistrict litigation over Celgene Corp.'s cancer drug Revlimid filed against Bristol-Myers Squibb, Natco Pharma, AbbVie and other pharmaceutical companies, ruling that buyers' pay-for-delay claims are plausible at this stage in the litigation.
May 06, 2026
A New Jersey federal judge won't ask the Supreme Court of Minnesota to weigh in on whether an insurer can pursue claims using a state law typically reserved for the attorney general in litigation alleging drugmaker Celgene used charitable donations to manipulate the price of cancer drugs.